Subsequent subgroup analyses revealed a notable correlation between elevated CGB5 expression and unfavorable OS outcomes in the following subgroups of GC patients: age > 65 years (P = 0.009), histological grade 3, pathological stage III, pathological T4 stage, pathological N2 stage, pathological M1 stage, and absence of residual tumor (Figure 8D). The gene discussed is CGB5; the disease is gastric cancer.